Loading
A phase 2 trial of epirubicin, cyclophosphamide, paclitaxel / nab-paclitaxel and carboplatin in triple-negative breast cancer, run by University College Hospital, Ibadan, now recruiting.
MicroRNA Profiles in Triple Negative Breast Cancer is a phase 2, interventional study registered as NCT04771871 by University College Hospital, Ibadan, with a registry enrolment figure of 42 participants, started 2021-11-29 and due to reach its primary completion in 2027-03. Interventions recorded: Epirubicin; Cyclophosphamide; Paclitaxel; Carboplatin. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Patients with histologically confirmed carcinoma of the female breast with triple negative status by immuno-histochemistry (IHC)". Sites: Nigeria. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Epirubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cyclophosphamide and the tag tnbc-deep-dive.
Shares Epirubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Paclitaxel / nab-paclitaxel and the tag tnbc-deep-dive.
Shares Epirubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cyclophosphamide and the tag tnbc-deep-dive.
Shares Epirubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cyclophosphamide and the tag tnbc-deep-dive.
Shares Epirubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cyclophosphamide and the tag tnbc-deep-dive.
Shares Epirubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cyclophosphamide and the tag tnbc-deep-dive.
Shares Epirubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents and the tag tnbc-deep-dive.
Shares Epirubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cyclophosphamide and the tag tnbc-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/